Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

著者: Enrique Grande, José Ángel Arranz, Maria De Santis, Aristotelis Bamias, Eiji Kikuchi, Xavier García del Muro, Se Hoon Park, Ugo De Giorgi, B. Yа. Alekseev, Marina Mencinger, Kouji Izumi, Fabio A.B. Schutz, Javier Puente, Jian‐Ri Li, Peter H. O’Donnell, Arash Rezazadeh Kalebasty, Dingwei Ye, Sanjeev Mariathasan, FabioIa Bene-Tchaleu, Sandrine Bernhard, Chooi Lee, Ian D. Davis, Matthew D. Galsky - The Lancet 2023 被引用: 55